Background and objective: It has been proven that icotinib hydrochloride, as a molecule targeted drug, can be safely and efficiently used to treat advanced non-small cell lung cancer (NSCLC) for second-line or third-line. This research was aimed to investigate the efficacy and toxicity of icotinib hydrochloride as the first-line therapy for pulmonary adenocarcinoma.
Results: Among the 56 patients, the tumor objective response rate (ORR) and disease control rate (DCR) was 46.4% (26/56) and 78.6% (46/56), respectively. Among the 20 patients with EGFR analyses, 18 patients were positive for a mutation, ORR was 66.7% (12/18), DCR was 94.4% (17/18) respectively. The ORR with no history of smoke. EGFR positive mutation and appearance of rash were significantly higher than those with smoker, wild type EGFR, no information about EGFR and no appearance of rash (P<0.05). The most common drug-related adverse events were mild skin rash (28.5%) and diarrhea (12%).
Conclusion: Single agent treatment with icotinib hydrochloride is effective and tolerable in first-line therapy for pulmonary adenocarcinoma, especially with EGFR mutation.
背景与目的 分子靶向治疗药物盐酸埃克替尼治疗复治晚期非小细胞肺癌具有较好的疗效和安全性。本文观察盐酸埃克替尼一线治疗晚期肺腺癌的近期疗效和毒副反应。 方法 对2011年8月-2012年11月间收治的56例初治晚期肺腺癌患者，口服盐酸埃克替尼125 mg，每日3次，评价近期疗效和不良反应。结果 56例肺腺癌患者的客观有效率为46.4%（26/56），疾病控制率为78.6%（44/56）。20例患者进行了EGFR基因突变检测，18例患者EGFR基因突变阳性，EGFR突变阳性患者的客观有效率为66.7%（12/18），疾病控制率为94.4%（17/18）。不吸烟、EGFR基因突变阳性和出现皮疹的患者客观有效率高于吸烟、EGFR基因野生型和突变情况未知、未出现皮疹的患者（P<0.05）。治疗相关毒副反应主要为轻度皮疹（28.5%）和腹泻（12%）。结论 盐酸埃克替尼一线治疗晚期肺腺癌疗效肯定，不良反应轻微，对于EGFR突变阳性患者有效率更高。